Immuno-chromatic probe based lateral flow assay for point-of-care detection of Japanese encephalitis virus NS1 protein biomarker in clinical samples using a smartphone-based approach

Roberts, Akanksha; Prakashan, Drishya; Dhanze, Himani; Gandham, Ravi Kumar; Gandhi, Sonu; Sharma, G. Taru

doi:10.1039/d2na00463a

Cited by 23 publications

(10 citation statements)

References 55 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 30 , 31 The sample pad and the conjugate pads are pretreated before assembly for the equilibration of the membrane, antifouling of the membrane pores, and easy flow of the analyte across the membrane. 29 Moreover, variations in conjugate deposition, drying, and membrane release, all contribute significantly to the coefficient of variation in test performance. The sample is loaded on the pretreated sample pad, enabling it for interaction with the AuNPs‐Ab probe deposited on the conjugate pad.…”

Section: Resultsmentioning

confidence: 99%

“…Several new labels such as colloidal gold nanoparticles (AuNPs), 24 , 25 gold nanorods, 26 silver enhancement technology, and carbon and magnetic nanomaterials 27 accompanied with enzymes (horseradish peroxidase) supports the improvement of quantification system, but their synthesis process is difficult and expensive. Therefore, AuNPs are prominently used in LFIA due to its unique optical property, biocompatibility with different biomolecules, stability, 28 , 29 cost‐effectiveness, and easy synthesis. Currently, several LFIAs have been developed and commercialized in the market, of which the majority of them are serological‐based assays and rely on previous SARS‐CoV‐2 exposure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application

Prakashan

Shrikrishna

Byakodi

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic has emphasized the need for development of a rapid diagnostic device for the effective treatment and its mitigation. Lateral flow immunoassay (LFIA) belongs to a class of diagnostic devices, which has the benefit of providing quick results, easy to handle, low cost, and on‐site applicable. So far, several LFIA has been developed for the detection of infectious severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2), however, only a few of them are antigen (Ag)‐based. Here, we describe an antibody (Ab)‐labeled gold nanoparticles (AuNPs)‐based LFIA (AuNPs‐LFIA) for the detection of Receptor‐Binding Domain (RBD) of SARS‐CoV‐2. For this, RBD Ab of SARS‐CoV‐2 was conjugated with the AuNPs, which served as a detecting probe. The fabricated LFIA strip was optimized for different parameters such as membrane pore size, blocking conditions, Ab coating concentration, and conjugate incubation. The optimized LFIA strips were validated in spiked buffer samples and the optimal limit of detection was found to be 1 ng/ml, which was confirmed by a smartphone‐based application. Moreover, the developed AuNPs‐LFIA strips effectively detected RBD Ag in 100 clinical samples with 94.3% sensitivity and 90.9% specificity in clinical samples when compared with the gold standard (RT‐PCR). The fabricated LFIAs are reported to have storage stability of up to 21 days at 4°C and room temperature (RT). Hence, the developed LFIA can be used as a portable, cost‐effective diagnostic device for rapid detection of SARS‐CoV‐2.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application

Prakashan

Shrikrishna

Byakodi

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In general, LFAs utilize antibodies as recognition elements and AuNPs as reporter probes, and the detection result is directly visualized on the test strip without requiring external energy sources [ 24 ]. For instance, Roberts et al reported a portable LFA for on-site detection of the Japanese Encephalitis virus in serum ( Figure 1 a) [ 25 ]. Using AuNPs as immunoprobes, the test line turned red in the presence of the antigen, with a limit of detection (LOD) of 10 pg/mL within 10 min.…”

Section: Virus Detection On Microfluidic Platformmentioning

confidence: 99%

“… ( a ) Schematic representation of the colorimetric sandwich-based LFA for rapid detection of the Japanese Encephalitis virus using gold nanoparticles. Reprinted with permission from [ 25 ]. Copyright (2022) RSC publications.…”

Section: Figurementioning

confidence: 99%

Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review

2023

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an ongoing coronavirus disease (COVID-19) outbreak and a rising demand for the development of accurate, timely, and cost-effective diagnostic tests for SARS-CoV-2 as well as other viral infections in general. Currently, traditional virus screening methods such as plate culturing and real-time PCR are considered the gold standard with accurate and sensitive results. However, these methods still require sophisticated equipment, trained personnel, and a long analysis time. Alternatively, with the integration of microfluidic and biosensor technologies, microfluidic-based biosensors offer the ability to perform sample preparation and simultaneous detection of many analyses in one platform. High sensitivity, accuracy, portability, low cost, high throughput, and real-time detection can be achieved using a single platform. This review presents recent advances in microfluidic-based biosensors from many works to demonstrate the advantages of merging the two technologies for sensing viruses. Different platforms for virus detection are classified into two main sections: immunoassays and molecular assays. Moreover, available commercial sensing tests are analyzed.

show abstract

“…The LFA was able to successfully detect JEV Ab in 500 clinical pig serum real samples with 100% relative diagnostic specificity as well as sensitivity in monsoon and post-monsoon (Dhanze et al 2019 ). Another recently developed LFA using AuNPs conjugated with JEV NS1 Ab as immunochromatic probes was fabricated for successful point of care detection of JEV NS1 Ag in clinical pig serum samples with a visual LOD of 10 pg/ml (Roberts et al 2022d ).…”

Section: Biosensors For Jev Diagnosticsmentioning

confidence: 99%

A brief review on novel biomarkers identified and advanced biosensing technologies developed for rapid diagnosis of Japanese Encephalitis Virus

Roberts

Gandhi

2022

Proc.Indian Natl. Sci. Acad.

Self Cite

View full text Add to dashboard Cite

Advanced biosensor technology research is imperative for the management of infectious disease outbreaks such as Japanese Encephalitis (JE), a zoonotic disease caused by the flavivirus JE virus (JEV) which is transmitted to humans (dead-end hosts) from the amplification host, pigs, via mosquitoes. To avoid future pandemic scenarios, proactive research rather than responsive research in the field of diagnostics is a requirement for development of rapid, sensitive and specific screening detection methods. In this mini-review, we have critically compared and evaluated the different types of biomarkers (antigen, antibody, nucleic acid) identified for JEV diagnostics and their specific roles in the manifestation of the infection which may be potentially used for therapeutics and drug development as no treatment is available for JE. Furthermore, different biosensors developed for the detection of JEV biomarkers have been discussed in detail to give an overview of the working principles (electrochemical, optical, etc.), fabrication components (signal amplifier, bioreceptor, etc.), detection limits and response times. This review provides a compact compiled base on available JEV diagnostic research work being currently carried out along with their limitations, future prospective, and major challenges faced. This will enable future development of rapid point-of-care diagnostic screening methods for JEV infection management, which may help reduce number of fatalities.

show abstract

Immuno-chromatic probe based lateral flow assay for point-of-care detection of Japanese encephalitis virus NS1 protein biomarker in clinical samples using a smartphone-based approach

Abstract: Lateral flow assays (LFAs) are one of the most economical, point-of-care (PoC) diagnostic assays that exploit the colorimetric properties of gold nanoparticles (AuNPs) but no rapid antigen-based LFA exists for...

Cited by 23 publications

References 55 publications

Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application

Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application

Recent Advances in Molecular and Immunological Diagnostic Platform for Virus Detection: A Review

A brief review on novel biomarkers identified and advanced biosensing technologies developed for rapid diagnosis of Japanese Encephalitis Virus

Contact Info

Product

Resources

About